Efavirenz

This classification denotes a reverse transcriptase inhibitor with the molecular formula C14H9ClF3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JE6H2O27P8, chemically known as 2h-3,1-benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4s)- but generally known as efavirenz, which bears US NIH Compound Identifier 64139. European Medicines Agency schedules Efavirenz in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06463MIG. The term EFAVIRENZ is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules efavirenz in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule efavirenz under HS 29349990 and SITC 51579. As of Q4 2014, EFAVIRENZ remains the US FDA Preferred Term for this commodity. Efavirenz bears US NLM identifiers UMLS ID C0674428 and NCI Concept Code C29027. SMILES: Clc1cc2C(OC(=O)Nc2cc1)(C#CC1CC1)C(F)(F)F.